Biocitech appoints new ceo

Jean-Francois Boussard becomes chief executive of French life science technology park on 1 April.

Jean-Francois Boussard will become chief executive of Biocitech, the French life science technology park in Paris, on 1 April. He replaces Jacques Lhomel, who is retiring to pursue personal projects.

Boussard joins Biocitech after a biotechnology career in academia and industry. From 1994, after six years as patents, licensing and legal director in a financial holding company, he became an independent consultant in enterprise creation and technology transfer. In 1998, he founded and was ceo of Substrat, a consultancy specialising in enterprise creation and management, project management and technology transfer in the field of biotechnology.

Prior to Substrat, Boussard was a manager for pharmaceuticals and biotechnology at France's innovation agency, Anvar, from 1982-88. From 1979-82, he was a biologist at LERS Synthelabo after an earlier spell as a research scientist at the University of Metz.

"I am looking forward to putting my scientific, legal and financial know-how to use to continue the rapid development of the park," said Boussard.

Biocitech provides offices, laboratories and technical and scientific services.

You may also like

You need to be a subscriber to read this article.
Click here to find out more.
Pharmaceutical

A bullish time for biotech

Biotechnology has changed healthcare radically over the past decade and its impact on the pharmaceutical sector is growing. Susan Birks reports on the impact of the biotech boom
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Subscribe now